The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | What’s next for patients with BRAF VJ600E mutant metastatic CRC?
Sebastian Stintzing, MD, Charite University Hospital, Berlin, Germany, discusses the next steps for patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), including the addition of chemotherapy plus targeted therapies to improve overall survival in the first-line setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
